NCT Number: NCT02511834
VEST III PMS Clinical Protocol
Post marketing surveillance (PMS) study. 200 patients will be enrolled in a prospective, multi center, randomized, two-arm, open label, and controlled, enrolling patients with multi vessel atherosclerotic coronary artery disease, scheduled to undergo Coronary artery bypass grafting (CABG) with arterial grafting of IMA to LAD, one saphenous vein graft (SVG) to the right territory and one or more SVGs to the left territory. Of all vein grafts, one will be selected randomly to receive treatment with VEST and another designated Control.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–80 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Medical University of Innsbruck, Innsbruck, Austria
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patient scheduled for on-pump CABG on clinical grounds
- Two or more bypass vein grafts bypasses indicated as follows: one (1) for right coronary artery, 1 or more for left coronary arteries and IMA indicated for the LAD on clinical grounds
- Appropriately sized and accessible target coronary arteries, with a minimum diameter of 1.5 mm and adequate vascular bed
- Ability to give their informed written consent
- Ability and willingness to comply with study follow up requirements
- Patient is ≥ 18 and ≤ 80 years of age, and has Life expectancy ≥5 years
Exclusion criteria
- Concomitant non-CABG cardiac procedure
- Prior cardiac surgery
- Emergency CABG surgery (cardiogenic shock, inotropic pressure support, IABP)
- Contraindication for on-pump CABG with cardioplegic arrest (e.g. severely calcified aorta)
- Calcification at the intended anastomotic sites, as assessed upon opening of the chest, before randomization
- Severe vein varicosity
- Prior debilitating stroke less than 1 year before surgery
- Severe renal dysfunction (Cr>2.0 mg/dL or >177 μmol/L)
- Women of child bearing age
- Concomitant life-threatening disease likely to limit life expectancy to less than 5 years
- Indication for Warfarin up to time of surgery
- Inability to tolerate or comply with required normal post-operative drug regimen (antiplatelet, statin and beta-blockers) that cannot adequately be controlled.
- inability to take aspirin
- Contraindication to intravascular contrast material that cannot be adequately controlled with pre-medication
- Inability to comply with required follow-ups including angiographic and/or CT imaging methods.
- Participating in any other investigational study for either drug or device which can influence collection of valid data under this study
Treatment and study plan
Coronary artery bypass surgery
ProcedureOther names: CABG
Primary outcomes
-
Proportion of Vein grafts with Fitzgibbon I patency score out of all grafts including occluded ones.
Time frame: 2 years
Perfect patency, no lumen irregularities. Rates out of all grafts including occluded ones.
Secondary outcomes
-
Intimal hyperplasia area
Time frame: 2 years
Sub group (IVUS) - Intimal hyperplasia (plaque+media) area [mm2] as assessed by IVUS
-
MACCE
Time frame: 2 years
Composite of: All-cause mortality; Stroke; Myocardial infarction; Coronary revascularization
-
Vein graft failure
Time frame: 2 years
Defined as ≥50% stenosis by QCA
-
Early vein graft failure
Time frame: 6 months
Early vein graft failure, defined as >50% occlusion by CT Angio
Sponsors and collaborators
Lead sponsor
Vascular Graft Solutions Ltd.
Industry
Registry information
Acronym: VEST III
Important dates
- Study start
- 2015
- Primary completion
- 2019
- Study completion
- 2019
- First posted
- Jul 30, 2015
- Registry last updated
- Jun 26, 2020
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Impact of Cardiac Rehabilitation on Patient Outcomes
NCT07468955
Arterial Occlusive Diseases, Arteriosclerosis
Kütahya, Center, Turkey (Türkiye)
View Trial DetailsA Sugar-Sweetened Beverage Reduction Intervention for Native American Men
NCT06029517
Arterial Occlusive Diseases, Arteriosclerosis
Buffalo, New York, United States
View Trial DetailsSafety and Effectiveness of Agent Paclitaxel-Coated PTCA Balloon Catheter. (AGENT Japan SV)
NCT04058990
Arterial Occlusive Diseases, Arteriosclerosis
Kitakyushu, Fukuoka, Japan
View Trial DetailsPROMUS PREMIER™ China Post-Approval Study
NCT03273023
Arterial Occlusive Diseases, Arteriosclerosis
Harbin, Heilongjiang, China
View Trial Details